Cell cycle deregulation in B-cell lymphomas

被引:285
|
作者
Sánchez-Beato, M [1 ]
Sánchez-Aguilera, A [1 ]
Piris, MA [1 ]
机构
[1] CNIO, Mol Pathol Program, Lymphoma Grp, E-28029 Madrid, Spain
关键词
D O I
10.1182/blood-2002-07-2009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disruption of the physiologic balance between cell proliferation and death is a universal feature of all cancers. In general terms, human B-cell lymphomas can be subdivided. into 2 main groups, to low- and high-growth fraction lymphomas, according to the mechanisms through which this imbalance is achieved. Most types of low-growth fraction lymphomas are initiated by molecular events resulting in the inhibition of apoptosis, such as translocations affecting BCL2, in follicular lymphoma, or BCL10 and API2/MLT1, in mucosa-associated lymphoid tissue (MALT) lymphomas. This results in cell accumulation as a consequence of prolonged cell survival. In contrast, high-growth fraction lymphomas are characterized by an enhanced proliferative activity, as a result of the deregulation of oncogenes with cell cycle regulatory functions, such as BCL6, in large B-cell lymphoma, or c-myc, in Burkift lymphoma. Low- and high-growth fraction lymphomas are both able to accumulate other alterations in cell cycle regulation, most frequently involving tumor suppressor genes such as p16(INK4a), p53, and p27(KIP1). As a consequence, these tumors behave as highly aggressive lymphomas. The simultaneous inactivation of several of these regulators confers in creased aggressivity and proliferative advantage to tumoral cells. In this review we discuss our current knowledge of the alterations in each of these pathways, with special emphasis on the deregulation of cell cycle progression, in an attempt to integrate the available information within a global model that describes the contribution of these molecular changes to the genesis and progression of B-cell lymphomas. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:1220 / 1235
页数:16
相关论文
共 50 条
  • [1] Translation deregulation in B-cell lymphomas
    Horvilleur, Emilie
    Wilson, Lindsay A.
    Willis, Anne E.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2010, 38 : 1593 - 1597
  • [2] LETTER TO THE EDITOR - MYC DEREGULATION IN B-CELL CUTANEOUS LYMPHOMAS
    Toni, G.
    La Mantia, E.
    Fiorentino, F.
    WORLD CANCER RESEARCH JOURNAL, 2020, 7
  • [3] Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas
    Bai, M
    Papoudou-Bai, A
    Kitsoulis, P
    Horianopoulos, N
    Kamina, S
    Agnantis, NJ
    Kanavaros, P
    IN VIVO, 2005, 19 (02): : 439 - 453
  • [4] Immunotherapy in the B-cell lymphomas
    Gribben, JG
    CYTOTHERAPY, 2002, 4 (05) : 439 - 440
  • [5] MONOCYTOID B-CELL LYMPHOMAS
    ISAACSON, PG
    SPENCER, J
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1990, 14 (09) : 888 - 890
  • [6] Aggressive B-cell lymphomas
    Yang, W
    Listinsky, CM
    UPDATES IN DIAGNOSTIC PATHOLOGY, 2005, 563 : 125 - 134
  • [7] Zandelisib and B-Cell Lymphomas
    O'Brien, Susan
    Zelenetz, Andrew D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 117 - 119
  • [8] Ibrutinib in B-cell Lymphomas
    Maddocks, Kami
    Blum, Kristie A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (02) : 226 - 237
  • [9] Cutaneous B-Cell Lymphomas
    Villasenor-Park, Jennifer
    Chung, Jina
    Kim, Ellen J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (05) : 1111 - 1131
  • [10] CLASSIFICATION OF B-CELL LYMPHOMAS
    NATHWANI, BN
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 255 - 255